Introduction
Many Solid dosage forms are provided with a coating. Generally these coatings are enteric coatings, which may be natural or synthetic. These coatings need to certain properties including being biodegradable, allowing for good coatability, provide gastric resistance, have good delayed release properties, have long term stability and contain no plasticizers
UCLan research has developed an improved enteric coating for solid dosage forms, an enteric coating and a method for preparing an enteric coating which provides improved functionality. for example to allow the active ingredients to get to the small intestine prior to being absorbed into the body, and in process satisfy all the requirement of an enteric coating.
Description
UCLan research has developed an improved enteric coating for solid dosage forms, the enteric coating and the method for preparing an enteric coating provide improved functionality, for example to allow the active ingredients to get to the small intestine prior to being absorbed into the body, and in process satisfy all the requirement of an enteric coating.
UCLan research’s work has produced an enteric coating which is made of natural ingredients. It enables solid dosage forms to be produced which have particularly desirable properties including being biodegradable, allowing for good coatability, providing gastric resistance, having good delayed release properties, having long term stability and containing no plasticizers.
The coatings exhibit excellent dissolution and disintegration pH thresholds for delayed release applications, thereby facilitating reliable transit of corresponding solid dosage forms through a variety of gastric environments at a variety of pHs whilst still enabling rapid release within the small intestine. In contrast to existing natural coatings, the coatings are highly stable upon prolonged storage or stressed conditions, meaning that delayed release properties are more reliable and consistent.
This development is particularly suited to the use with 3D printing technology, specifically fused filament fabrication (FFF) 3D printing, to produce solid dosage forms as described in other IP owned by UCLan.
UCLan research has a suite of patents which all relate to the principal of 3D printing of solid dosage forms. The patents are available individually, or in a package. This case is the key patent in this suite which may be required to practice some of the other patents. We believe that it is possible to practice this patent independent of the rest of the IP portfolio, so this patent is available alone, however, it is also available as part of the suite of patents.
Core Advantages
- The coatings use natural ingredients which provide greater biodegradability and environmental sustainability.
- The coatings are capable of facilitating reliable transit of corresponding solid dosage forms through a variety of gastric environments.
- The coatings have delayed release properties.
- The coatings have aesthetically-pleasing.
- Coatings provide these properties without using plasticizers.
Application
- The technology enables pharmaceuticals to be produced such that they allow for delayed release.
- The technology also enables drugs to be absorbed into the body in the desired places.